NanoViricides Reports Strong Anti-Measles Results for NV-387 Antiviral Candidate

NanoViricides, Inc. announced that CEO Dr. Anil Diwan discussed significant progress in the company's antiviral research during a video interview available at https://youtu.be/m_3Yk4_832E. The company's lead candidate, NV-387, demonstrated strong anti-Measles activity in both cell culture and humanized animal models, showing particularly promising results in severe infection stages. The drug extended survival by 130% and provided protection to lung tissue, which is critical given the respiratory complications often associated with Measles infections.

The findings are especially significant because there are currently no approved treatments specifically for Measles virus infection. This represents a major unmet medical need globally, particularly in regions experiencing Measles outbreaks. The broad-spectrum potential of NV-387 positions it as a potentially valuable therapeutic option for healthcare providers facing Measles cases. The company's platform technology, licensed from TheraCour Pharma, Inc., forms the basis for this novel class of antiviral drug candidates.

NV-387 has already completed Phase I human clinical trials with no reportable adverse events, establishing an important safety profile for the drug candidate. The company is now advancing the drug to Phase II trials for MPox, another viral indication. This progression through clinical development stages demonstrates the compound's potential across multiple viral targets. The company maintains a comprehensive development pipeline that includes drugs against various viral diseases including RSV, COVID, Long COVID, Influenza, and other respiratory viral infections.

NanoViricides is positioned to support FDA emergency use applications and investigator-initiated Investigational New Drug applications for urgent Measles cases. This regulatory preparedness could prove crucial in responding to Measles outbreaks where immediate therapeutic intervention is needed. The company's business model relies on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation. Additional information about the company's developments is available through their newsroom at https://ibn.fm/NNVC.

The company's broader development efforts extend beyond Measles and MPox to include programs targeting oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus among others. This comprehensive approach to antiviral development reflects the company's commitment to addressing multiple viral threats through its proprietary nanoviricide technology platform. The successful demonstration of anti-Measles activity adds another important dimension to the drug's potential clinical utility and market applications.